Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Hayden

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
Scientific Reports|March 16, 2019
Author Correction: Laquinimod treatment in the R6/2 mouse modelGisa Ellrichmann, Alina Blusch, Oluwaseun Fatoba, et al.
American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics|December 24, 2002
CAG repeat polymorphisms in KCNN3 (HSKCa3) and PPP2R2B show no association or linkage to schizophreniaClaudine Laurent, Dana Niehaus, Stéphanie Bauché, et al.
Journal of Huntington'S Disease|June 9, 2020
Additional Safety and Exploratory Efficacy Data at 48 and 60 Months from Open-HART, an Open-Label Extension Study of Pridopidine in Huntington DiseaseAndrew McGarry, Peggy Auinger, Karl Kieburtz, et al.
Archives of Neurology|June 14, 2006
Preparing for preventive clinical trials: the Predict-HD studyJane S Paulsen, Michael Hayden, Julie C Stout, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|August 13, 2010
Cholesterol defect is marked across multiple rodent models of Huntington's disease and is manifest in astrocytesMarta Valenza, Valerio Leoni, Joanna M Karasinska, et al.
The Lancet. Neurology|December 20, 2018
Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging studyRalf Reilmann, Andrew McGarry, Igor D Grachev, et al.
Redox Biology|August 21, 2022
Mitochondrial and redox modifications in early stages of Huntington's diseaseCarla Lopes, I Luísa Ferreira, Carina Maranga, et al.
Eneurologicalsci|December 15, 2018
Response to the Letter-to-the Editor by Cohen et al. concerning our eNeurologicalSci article, Melamed-Gal, et al. Physicochemical, biological, functional and toxicological characterization of the European follow-on glatiramer acetate product as compared with Copaxone. eNeurologicalSci 2018;12:19-30.https://doi.org/10.1016/j.ensci.2018.05.006Sigal Melamed-Gal, Pippa Loupe, Bracha Timan, et al.
The Lancet. Neurology|January 27, 2024
Safety and efficacy of laquinimod for Huntington's disease (LEGATO-HD): a multicentre, randomised, double-blind, placebo-controlled, phase 2 studyRalf Reilmann, Karen E Anderson, Andrew Feigin, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 23, 2023
Potent, Gut-Restricted Inhibitors of Divalent Metal Transporter 1: Preclinical Efficacy against Iron Overload and Safety EvaluationAlison Cutts, Sultan Chowdhury, Laszlo G Ratkay, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Scientific Reports|March 16, 2019
Author Correction: Laquinimod treatment in the R6/2 mouse modelGisa Ellrichmann, Alina Blusch, Oluwaseun Fatoba, et al.
American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics|December 24, 2002
CAG repeat polymorphisms in KCNN3 (HSKCa3) and PPP2R2B show no association or linkage to schizophreniaClaudine Laurent, Dana Niehaus, Stéphanie Bauché, et al.
Journal of Huntington'S Disease|June 9, 2020
Additional Safety and Exploratory Efficacy Data at 48 and 60 Months from Open-HART, an Open-Label Extension Study of Pridopidine in Huntington DiseaseAndrew McGarry, Peggy Auinger, Karl Kieburtz, et al.
Archives of Neurology|June 14, 2006
Preparing for preventive clinical trials: the Predict-HD studyJane S Paulsen, Michael Hayden, Julie C Stout, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|August 13, 2010
Cholesterol defect is marked across multiple rodent models of Huntington's disease and is manifest in astrocytesMarta Valenza, Valerio Leoni, Joanna M Karasinska, et al.
The Lancet. Neurology|December 20, 2018
Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging studyRalf Reilmann, Andrew McGarry, Igor D Grachev, et al.
Redox Biology|August 21, 2022
Mitochondrial and redox modifications in early stages of Huntington's diseaseCarla Lopes, I Luísa Ferreira, Carina Maranga, et al.
Eneurologicalsci|December 15, 2018
Response to the Letter-to-the Editor by Cohen et al. concerning our eNeurologicalSci article, Melamed-Gal, et al. Physicochemical, biological, functional and toxicological characterization of the European follow-on glatiramer acetate product as compared with Copaxone. eNeurologicalSci 2018;12:19-30.https://doi.org/10.1016/j.ensci.2018.05.006Sigal Melamed-Gal, Pippa Loupe, Bracha Timan, et al.
The Lancet. Neurology|January 27, 2024
Safety and efficacy of laquinimod for Huntington's disease (LEGATO-HD): a multicentre, randomised, double-blind, placebo-controlled, phase 2 studyRalf Reilmann, Karen E Anderson, Andrew Feigin, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 23, 2023
Potent, Gut-Restricted Inhibitors of Divalent Metal Transporter 1: Preclinical Efficacy against Iron Overload and Safety EvaluationAlison Cutts, Sultan Chowdhury, Laszlo G Ratkay, et al.
Pageof 5